Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...
Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer ...
Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...
malaymail on MSN4d
GSK’s Arexvy vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in MalaysiaGlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy (MAL24086007ARZ) has been approved in Malaysia for ...
Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV ...
Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding.
These include the demand and stocking levels for US Arexvy, trends for Shingrix in the US market, and the development of the company's partnership in China. Additionally, the potential impact of ...
The revision comes as the analyst anticipates GlaxoSmithKline's third-quarter sales and profits to likely fall short of consensus estimates, primarily due to weaker than expected performance of US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback